Condition
HER2 Negative Breast Neoplasms
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
75.0%
3 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Terminated3
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04389632Phase 1Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT05194072Phase 1Terminated
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT04665921Phase 1Terminated
A Study of SGN-STNV in Advanced Solid Tumors
NCT04042480Phase 1Terminated
A Study of SGN-CD228A in Advanced Solid Tumors
Showing all 4 trials